摘要
目的探讨低剂量硼替佐米联合阿霉素及地塞米松治疗多发性骨髓瘤临床效果。方法将45例多发性骨髓瘤患者随机分为观察组23例和对照组22例。对照组采用常规剂量硼替佐米联合阿霉素及地塞米松治疗,观察组采用减低剂量硼替佐米联合阿霉素及地塞米松治疗。观察2组患者的治疗效果,疾病进展时间,不良反应发生情况及患者术后生活质量的改善情况。结果观察组和对照组的治疗有效率分别为52.17%和40.91%,差异无统计学意义(χ2=0.5733,P=0.4490);观察组和对照组的疾病控制率分别为86.96%和81.82%,差异也无统计学意义(χ2=0.2260,P=0.6345)。2组患者疾病进展时间为3~10个月,观察组平均进展期(5.78±2.12)个月;对照组平均进展期(5.82±2.08)个月,差异无统计学意义(t=0.0639,P=0.9494)。2组患者治疗后主要的胃肠毒性的发生率和带状疱疹的发生率比较,差异有统计学意义(P<0.05),而血液毒性各项不良反应发生率大致相当,差异均无统计学意义(P>0.05)。2组患者治疗后的生活质量评分比较,差异无统计学意义(χ2=0.8756,P=0.3494)。结论低剂量硼替佐米联合阿霉素及地塞米松治疗多发性骨髓瘤的疗效与常规剂量相当,且不良反应较小,适合临床长期推广应用。
Objective To analyze the clinical effects of low-dose bortezomib combined with doxorubicin and dexamethasone in the treatment of multiple myeloma. Methods 45 cases of multiple myeloma were randomly divided into the observation group( 23 cases) and the control group( 22 cases),the control group received conventional dose bortezomib combinaed with doxorubicin and dexamethasone,the observation group received low-dose doxorubicin combined with doxorubicin and dexamethasone.The treatment effects,time to disease progression,improvement of quality of life of the 2 groups were observed. Results The treatment efficiency of the 2 groups were 52. 17% and 40. 91%,respectively,the difference was not statistically significant( χ2=0. 5733,P = 0. 4490),the disease control rates between the 2 groups was no statistically significant difference( χ2= 0. 2260,P =0. 6345). All patients completed a course of treatment,and the follow-up process did not appear lost cases or deaths,the time to progression of the 2 groups was 3 to 10 months,the average progress of the observation group was 5. 78 ± 2. 12 months,the control group was 5. 82 ± 2. 08 months,the difference was not statistically significant( t = 0. 0639,P = 0. 9494). The incidence of gastrointestinal toxicity and herpes zoster after treatment between the 2 groups had statistically significant difference( P < 0. 05). After treatment,the various hematological toxicity of adverse reactions roughly had same incidence,the difference was not statistically significant( P > 0. 05),quality of life between the 2 groups had no statistically significant difference( χ2= 0. 8756,P = 0. 3494).Conclusion Low-dose bortezomib combinaed with doxorubicin and dexamethasone in the treatment of multiple myeloma is equally effective with less adverse reactions,and it is suitable for long-term clinical application.
出处
《实用癌症杂志》
2015年第1期69-71,共3页
The Practical Journal of Cancer
